Functional neuroimaging in Parkinson's disease (Q38088371)

28 August 2017

title

Functional neuroimaging in Parkinson's disease (English)

1 reference

28 August 2017

0 references

functional neuroimaging

1 reference

4

Vesna Sossi

1 reference

28 August 2017

Silke Appel-Cresswell

0 references

author name string

Raúl de la Fuente-Fernández

series ordinal

1

1 reference

28 August 2017

Silke Appel-Cresswell

series ordinal

2

1 reference

28 August 2017

Doris J Doudet

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Medical Diagnostics

28 August 2017

published in

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

109-120

1 reference

Epidemiology of Parkinson's disease

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Biochemical aspects of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Parkinson's disease: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopa decarboxylase activity of the living human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Visualizing vesicular dopamine dynamics in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

A reversible tracer analysis approach to the study of effective dopamine turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Imaging of compensatory mechanisms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Imaging endogenous dopamine competition with [11C]raclopride in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Quantification of Parkinson's disease-related network expression with ECD SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopamine D2 receptor density remains constant in treated Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

How useful is [123I]beta-CIT SPECT in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Assessment of the progression of Parkinson's disease: a metabolic network approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The role of radiotracer imaging in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopaminergic function and progression of Parkinson's disease: PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Changes in network activity with the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?--a [99mTc]-TRODAT-1 SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Presymptomatic compensation in Parkinson's disease is not dopamine-mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

In vivo studies on striatal dopamine D 1 and D 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Compulsive drug use linked to sensitized ventral striatal dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Trials of neuroprotective therapies for Parkinson's disease: problems and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopamine release in human ventral striatum and expectation of reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Metabolic brain networks associated with cognitive function in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Visual hallucination in Parkinson's disease with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

A pathological study of the association between Lewy body disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Functional abnormalities underlying pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Fatigue in levodopa-naive subjects with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Is the mesocortical dopaminergic system involved in Parkinson disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Functional and anatomical magnetic resonance imaging in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Enhancement of brain activation during trial-and-error sequence learning in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Functional changes in the activity of cerebellum and frontostriatal regions during externally and internally timed movement in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Role of hyperactive cerebellum and motor cortex in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Mapping the network for planning: a correlational PET activation study with the Tower of London task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopaminergic modulation of cortical function in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Neural bases of set-shifting deficits in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Cortical activity in Parkinson's disease during executive processing depends on striatal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Motor reserve and novel area recruitment: amplitude and spatial characteristics of compensation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Effective connectivity of neural networks in automatic movements in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Joint amplitude and connectivity compensatory mechanisms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Reporting of precision of estimates for diagnostic accuracy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Use of methodological standards in diagnostic test research. Getting better but still not good.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Age and severity of nigrostriatal damage at onset of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Prevalence of repetitive and reward-seeking behaviors in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Self-initiated versus externally triggered movements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

Depression in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2011.554820

10.1517/17530059.2011.554820

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference